PMID- 22670779
OWN - NLM
STAT- MEDLINE
DCOM- 20120820
LR  - 20240512
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 169
IP  - 1
DP  - 2012 Jul
TI  - Comparison of American and European practices in the management of patients with 
      primary immunodeficiencies.
PG  - 57-69
LID - 10.1111/j.1365-2249.2012.04588.x [doi]
AB  - Primary immunodeficiency diseases (PIDs) comprise a heterogeneous group of rare 
      disorders. This study was devised in order to compare management of these 
      diseases in the northern hemisphere, given the variability of practice among 
      clinicians in North America. The members of two international societies for 
      clinical immunologists were asked about their management protocols in relation to 
      their PID practice. An anonymous internet questionnaire, used previously for a 
      survey of the American Academy of Allergy, Asthma and Immunology (AAAAI), was 
      offered to all full members of the European Society for Immunodeficiency (ESID). 
      The replies were analysed in three groups, according to the proportion of PID 
      patients in the practice of each respondent; this resulted in two groups from 
      North America and one from Europe. The 123 responses from ESID members (23.7%) 
      were, in the majority, very similar to those of AAAAI respondents, with > 10% of 
      their practice devoted to primary immunodeficiency. There were major differences 
      between the responses of these two groups and those of the general AAAAI 
      respondents whose clinical practice was composed of < 10% of PID patients. These 
      differences included the routine use of intravenous immunoglobulin therapy (IVIg) 
      for particular types of PIDs, initial levels of IVIg doses, dosing intervals, 
      routine use of prophylactic antibiotics, perceptions of the usefulness of 
      subcutaneous immunoglobulin therapy (SCIg) and of the risk to patients' health of 
      policies adopted by health-care funders. Differences in practice were identified 
      and are discussed in terms of methods of health-care provision, which suggest 
      future studies for ensuring continuation of appropriate levels of immunoglobulin 
      replacement therapies.
CI  - (c) 2012 The Authors. Clinical and Experimental Immunology (c) 2012 British Society 
      for Immunology.
FAU - Hernandez-Trujillo, H S
AU  - Hernandez-Trujillo HS
AD  - University of Pennsylvania School of Medicine, Philadelphia, USA. 
      hernandeztrujilloh@email.chop.edu
FAU - Chapel, H
AU  - Chapel H
FAU - Lo Re, V 3rd
AU  - Lo Re V 3rd
FAU - Notarangelo, L D
AU  - Notarangelo LD
FAU - Gathmann, B
AU  - Gathmann B
FAU - Grimbacher, B
AU  - Grimbacher B
FAU - Boyle, J M
AU  - Boyle JM
FAU - Hernandez-Trujillo, V P
AU  - Hernandez-Trujillo VP
FAU - Scalchunes, C
AU  - Scalchunes C
FAU - Boyle, M L
AU  - Boyle ML
FAU - Orange, J S
AU  - Orange JS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Academies and Institutes
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Europe
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Deficiency Syndromes/*therapy
MH  - Internet
MH  - North America
MH  - Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Surveys and Questionnaires
PMC - PMC3390474
EDAT- 2012/06/08 06:00
MHDA- 2012/08/21 06:00
PMCR- 2013/07/01
CRDT- 2012/06/08 06:00
PHST- 2012/06/08 06:00 [entrez]
PHST- 2012/06/08 06:00 [pubmed]
PHST- 2012/08/21 06:00 [medline]
PHST- 2013/07/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2249.2012.04588.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2012 Jul;169(1):57-69. doi: 10.1111/j.1365-2249.2012.04588.x.